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Available online 21 January 2016Background: Aminoglycoside O-phosphotransferases make up a large class of bacterial enzymes that is widely
distributed among pathogens and confer a high resistance to several clinically used aminoglycoside antibiotics.
Aminoglycoside 2″-phosphotransferase IVa, APH(2″)-IVa, is an important member of this class, but there is little
information on the thermodynamics of aminoglycoside binding and on the nature of its rate-limiting step.
Methods:We used isothermal titration calorimetry, electrostatic potential calculations, molecular dynamics sim-
ulations and X-ray crystallography to study the interactions between the enzyme and different aminoglycosides.
We determined the rate-limiting step of the reaction by the means of transient kinetic measurements.
Results: For theﬁrst time, Kd valueswere determined directly for APH(2″)-IVa and different aminoglycosides. The
afﬁnity of the enzyme seems to anti-correlate with the molecular weight of the ligand, suggesting a limited
degree of freedom in the binding site. The main interactions are electrostatic bonds between the positively
charged amino groups of aminoglycosides and Glu or Asp residues of APH. In spite of the signiﬁcantly different
ratio Kd/Km, there is no large difference in the transient kinetics obtained with the different aminoglycosides.
We show that a product release step is rate-limiting for the overall reaction.
Conclusions: APH(2″)-IVa has a higher afﬁnity for aminoglycosides carrying an amino group in 2′ and 6′,
but tighter bindings do not correlate with higher catalytic efﬁciencies. As with APH(3′)-IIIa, an intermediate
containing product is preponderant during the steady state.
General signiﬁcance: This intermediate may constitute a good target for future drug design.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Bacterial infections are the cause of diseases that are often fatal
and highly contagious. The generalized introduction of antibioticsosphotransferases; APH(3′),
ﬁciency; NCNO, number of non-
ce.
, F-34293 Montpellier Cedex 5,
).
logie de Monastir, Faculty of
Wilson Avenue, Arlington, VA
. This is an open access article underafter the SecondWorldWar was one of themost important therapeutic
progresses of the 20th century. However, themisuse and over use of an-
tibiotics in the past decades have led to the emergence of several resis-
tant bacteria strains [1]. Bacteria have developed several strategies to
combat antibiotics. Of these, the mechanisms whereby bacteria express
enzymes that chemically inactivate antibiotics such as aminoglycosides
are of particular interest. There are more than 120 bacterial enzymes
that inactivate aminoglycosides by N-acetylation, O-adenylation or O-
phosphorylation [2]. Aminoglycoside phosphotransferases, APHs, cata-
lyze the transfer of a phosphate to a hydroxyl group of the antibiotic.
The location of the carbon atom carrying the modiﬁed group is speciﬁc
to each subclass of APH. The most common subclasses are APH(3′)
that modify the hydroxyl on the carbon 3 of ring A of the aminoglyco-
side, and APH(2″) on carbon 2 of the ring C. The name of the subclass
of APH is followed by a roman numeral that distinguishes enzymesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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zymes are indicated by a lower case letter.
APH(2″)-IVa confers a high level of resistance in several Enterococcus
strains towards various aminoglycosides that are prescribed in clinics,
and it can use either ATP or GTP as phospho-donor. The ﬁrst report of
the gene encoding this enzyme was by Tsai et al. [4]. By the use of an
enzyme coupled assay, Toth et al. showed that APH(2″)-IVa can phos-
phorylate all 4,6-disubstituted aminoglycosides, but not the 4,5-
disubstituted ones [3]. In a subsequent paper, Toth et al. reported the
steady state parameters, kcat andKm, of this enzymewith several amino-
glycosides and they solved the crystal structure of the apoprotein [5].
They attempted to explain its aminoglycoside speciﬁcity by a molecular
modeling study that involved the homologous APH(2″)-IIa. One year
later, Shi et al. determined the crystal structures of APH(2″)-IVa com-
plexed with tobramycin or kanamycin A [6].
Here, we obtained information on the thermodynamics of binding of
different aminoglycosides to APH(2″)-IVa by isothermal titration calo-
rimetry. We used crystal structures, complemented with surface poten-
tial calculations and molecular dynamics simulation of aminoglycoside
release, to describe important interactions between the antibiotics and
the enzyme.
To date, there is little information on the reaction pathway of
APH(2″)-IVa, apart from the studies of Toth et al. [5] who showed that
the reaction of APH(2″)-IVa proceeds by a Bi–Bi mechanism in which
aminoglycoside and ATP or GTP bind randomly. To fully understand
the mechanism of action of an enzyme, one must obtain information
on the nature and the rate of interconversion of the intermediates that
make up its reaction pathway. This can hardly be obtained from steady
state and equilibrium studies alone — it requires transient kinetics [7].
Here, we used a direct quench–ﬂow method, allowing both steady
state and transient kinetic measurements, to obtain the time course of
total ADP production (APH-bound plus free). Combining this method
with free ADP time course measurements using a ﬂuorescent biosensor
in a stopped–ﬂow apparatus, has allowed us to determine the nature of
the rate-limiting step of the reaction.
2. Materials and methods
2.1. Chemicals
All aminoglycosides, ATP and other chemicals were obtained from
Sigma-Aldrich at the highest purity grade. For control experiments,
the sulfate ions contained in the commercialized aminoglycoside pow-
ders were removed by Ba(OH)2 treatment as described elsewhere [8].
However, the presence of sulfate did not affect the thermodynamic
and kinetic parameters. Therefore, sulfate was not removed for subse-
quent experiments. Equimolar concentrations of MgCl2 were added to
ATP stock solutions. In the text, unless otherwise stated, ATP refers to
MgATP. Aminoglycoside and ATP stock solutions were prepared in
50 mM Tris–HCl, 40 mM KCl and 1 mM free MgCl2 and were stored at
−20 °C after adjusting pH to 7.5.
2.2. Protein puriﬁcation
Recombinant APH(2″)-IVa from Enterococcus casseliﬂavus was pro-
duced in Escherichia coli BL21 (DE3) transformed with pET15b plasmid
encoding for APH(2″)-IVa with a 6His-tag in N-terminal. aph(2″)-IVa
gene was the generous gift of Professor Vakulenko, Notre Dame, USA.
Two liters of Luria Brothmedia, LB, supplementedwith 0.1mg/mL of
Ampicillin, was inoculated at a ﬁnal OD600 nm of 0.1with a 100mL over-
night starting culture. Cells were grown at 37 °C with an agitation of
180 rpm. Protein expression was induced at the late mid log phase
(OD600 nm = 0.9) with 1 mM ﬁnal concentration of IPTG. After an over-
night incubation at 20 °C, cells were harvested by centrifugation and the
pellet was solubilized in 40 mL of lysis buffer (50 mM NaH2PO4 at
pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM DTT and 1 tablet ofcomplete™ EDTA-free protease inhibitor). Bacteria were lysed on
ice by sonication. Cell debris were removed by centrifugation and ultra-
centrifugation steps before loading the supernatant on a HisTrap FF
5 mL column in an Aktä Puriﬁer system (GE Healthcare). The enzyme
was eluted from the columnwith lysis buffer complemented with a lin-
ear gradient up to 500mMof imidazole. Pure fractionswere pooled and
the protein was concentrated to 30–50 mg/mL on a 30 kDa Centricon®
device (Millipore). The elution bufferwas exchanged by a storage buffer
containing 50 mM Hepes at pH 7.5, 50% glycerol and 1 mM DTT. The
protein was stored at−20 °C. Typical production yield was 80 mg/L of
culture.
To improve protein purity for the ITC experiments and crystallo-
genesis, a supplementary gel ﬁltration step was carried out on a HiLoad
16/60 Superdex 75 column (GE Healthcare) in either 50 mM Tris–HCl
pH 7.5, 40 mM KCl, 1 mM MgCl2 for ITC or in 50 mM Hepes pH 7.5,
10 mMMgCl2 for crystallization assays.
The catalytic activity of APH(2″)-IVa was independent of the pres-
ence of the 6His-tag, as controlled by comparing the steady state rates
obtained with kanamycin A before and after cleavage of the tagged pro-
teinwith thrombin (data not shown). The 6His-tag has also no effect on
the crystallogenesis of the protein. Therefore, in all experiments the
6His-tag was kept at the N-terminal part of the enzyme.
2.3. Isothermal titration calorimetry experiments
The enzyme was extensively dialyzed against buffer containing
50mMTris–HCl at pH 7.5, 40mMKCl, 1mMMgCl2 and ligand solutions
were prepared at 5 mM in the ﬁnal dialysate with readjusting pH to 7.5.
The enzyme was used at a ﬁnal concentration of 150 μM. ITC experi-
ments were carried out at 25 °C in a VP-ITC calorimeter (MicroCal, GE
Healthcare). Titrations consisted of 40 injections of 5 μL of ligand
every 300 s. The cell stirring speed was 300 rpm. To obtain reliable dis-
sociation constants, the c-value, a unitless parameter obtained by the
multiplication of the association constant and the total concentration
of ligand binding sites, was kept between 1.8 and 100 for all titrations.
Control runs were performed by titrating ligands to buffer, and the
resulting background signal was subtracted from the corresponding ex-
perimental data. Experiments were carried out at 1 mM free Mg2+.
Binding and thermodynamic parameters Ka (association constant),
ΔH (enthalpy change) and stoichiometry were obtained by nonlinear
least-squares ﬁtting of experimental data using a single-site binding
model of the Origin software package (version 5.0) provided with the
instrument. The free energy of binding (ΔG) and entropy change at
25 °C (ΔS) were obtained using the following equations:
ΔG ¼ –RT ln Kað Þ ð1Þ
ΔG ¼ ΔH–TΔS ð2Þ
The experiments were performed in triplicate (except with G418
and kanamycin B, in duplicate) and the error values given in the tables
are standard deviations.
2.4. Electrostatic potential and free energy calculations
Electrostatic potential surfaces were computed with the APBS pro-
gram [9]. The charges and radius of all atoms were calculated using
PDB2PQR software [10]. The linearized traditional Poisson–Boltzmann
equation was solved with APBS using a cubic spline charge discre-
tization and with dielectric constants of 2.0 for the solute and 78 for
the solvent at 300 K. Electrostatic potential is represented by a positive
and a negative isosurface at ±10 KbT/e (Kb, Boltzmann's constant; T,
temperature and e, charge of an electron).
All molecular dynamics simulations were performed using the
NAMD 2.10 software [11] in the isobaric–isothermal ensemble. The
pressure (1 atm) and temperature (300 K) were kept constant using
Table 1
Data collection and reﬁnement statistics of APH(2″)-IVa ∙ aminoglycoside complexes.
Values in parentheses refer to reﬂections in the highest-resolution shell. Ramachandran
statistics are from Coot.
Aminoglycosides G418 Sisomicin
PDB code 5C4K 5C4L
Data collection
Temperature (K) 298 100
Space group P 1 21 1 P 1 21 1
Cell dimensions
a, b, c (Å) 78.70, 64.94, 78.87 74.21, 65.11, 78.89
α, β, γ (°) 90.00, 90.73, 90.00 90.00, 91.16, 90.00
Resolution (Å) 42.44–3.05 (3.16–3.05) 37.10–2.35 (2.43–2.35)
Rsym or Rmergea 0.067 (0.318) 0.034 (0.230)
I/σI 5.5 (1.9) 8.9 (2.5)
Completeness (%) 90.0 (94.8) 94.7 (96.6)
Redundancy 1.6 (1.5) 1.9 (1.9)
Reﬁnement
Resolution (Å) 42.44–3.05 37.10–2.35
No. of reﬂections 13,126 28,377
Rwork
b 0.1591 0.2270
Rfree
c 0.1992 0.2784
No. of atoms
Protein 4930 4893
Ligand 34 41
Water / 55
B-factors
Protein (Å2) 38.1 38.4
Ligand (Å2) 123.1 72.0
Water (Å2) / 47.4
Rms deviations
Bond lengths (Å) 0.012 0.013
Bond angles (°) 1.515 1.538
Ramachandran statistics
Preferred region (%) 93.7 95.4
Allowed region (%) 6.3 4.3
Outliers (%) 0 0.3
a Rsym= ΣhklΣi│Ii(hkl)− 〈I(hkl)〉│ / ΣhklΣiIi(hkl), where 〈I(hkl)〉 is the average intensity
of equivalent reﬂections and the sum is extended over all measured observations for all
unique reﬂections.
b Rwork = Σhkl(|Fo|− |Fc|) / Σhkl|Fo|, where |Fo| is the observed and |Fc| the calculated
structure factor amplitude of a reﬂection.
c Rfree was calculated by randomly omitting 5% of the observed reﬂections before
reﬁnement.
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tein atoms were described by the CHARMM27 force ﬁeld [14] while
the aminoglycosides were parameterized using the paratool plugin im-
plemented in VMD [15] by assigning both the atomic partial charges
computed with Gaussian (by ﬁtting the electrostatic potential surface,
ESP) and atom types from CHARMM27. The crystal structures contain-
ing either kanamycin A (PDB: 4DFB) or tobramycin (PDB: 3SG8) were
immersed in a rectangular water box (TIP3 model) with a 12 Å thick-
ness and neutralized with three or four Na+ ions. As the crystal struc-
ture of APH(2″)-IVa·sisomicin was not fully solved or unsatisfactory,
the complex was obtained by docking (GOLD 5.2 program, CCDC Soft-
ware Limited) into the chain B of the 4DFB crystal structure. Kanamycin
was ﬁrst removed and used as a center for the search of binding modes
(docking poses) of sisomicin by applying 50 runs of genetic algorithms.
Solutions were classiﬁed according to their scores using the goldscore
function. This complex was immersed in a water box as the two other
aminoglycosides. The solvated systems were replicated in each direc-
tion using periodic boundary conditions. The short-range Lennard–
Jones potential was smoothly truncated from 10 to 12 Å and the PME
(Particle Mesh Ewald) algorithm [16] was used to calculate long-range
electrostatics with a grid spacing of 1 Å. The potential energy of themo-
lecular systems was minimized for 50,000 steps of conjugate gradient
(time step of 1 fs). After a gradual heating from 0 to 300 K, the two sys-
tems were further equilibrated for 100,000 steps. To explore the “un-
binding” of the aminoglycoside from the APH binding site, a reaction
coordinate was deﬁned as the distance separating the center of mass
of each entity (antibiotic and protein). A biased force was applied
using Colvars module of NAMD in order to estimate the free energy
change along the reaction coordinates using the ABF method [17]. The
distance separating the two centers of mass was initially 7.5 Å and
forced to reach 27.5 Å. A width of 0.1 Å was selected using four short
window (5 Å) simulations (6 ns each) and the ﬁnal potential of mean
force (PMF) was reconstructed from these separate windows. Simula-
tions were carried out on IBM blade cluster and trajectories were ana-
lyzed using VMD.
2.5. Crystal structure determination
Crystals of binary complexes of APH(2″)-IVa were grown at 18 °C
using similar conditions to those previously described by Toth et al.
[18]. Co-crystallization of the enzyme with either sisomicin or G418
(Geneticin) was carried out by mixing 1 μL of protein (6 mg/mL−1)
and aminoglycoside (2.5 mM) in 50 mM Hepes pH 7.5, 10 mM MgCl2
with 1 μL of reservoir solution composed of 12% PEG3350 (w/v),
50–75 mM ammonium citrate at pH 7.4 to 7.9.
Crystals of binary complex APH(2″)-IVa·sisomicin were grown by
the hanging drop vapor diffusion method over a reservoir of 500 μL.
After 2–3 days, crystals with approximate dimensions of 300 × 100 ×
50 μmwere observed. Theywere brieﬂy immersed in the reservoir solu-
tion supplemented with 15% of glycerol as cryoprotectant before being
ﬂash-cooled in liquid nitrogen. Data were collected under cryogenic
conditions on a Pilatus 6M-F detector at ESRF (Grenoble, France) on
beamline ID23-1. Crystals of binary complex APH(2″)-IVa·G418 were
grown by the sitting drop vapor diffusion method over a reservoir of
40 μL. The approximate size of crystals was 100 × 50 × 50 μm. Data col-
lection was carried out in situ as described by Gelin et al. [19] in a 96-
well CrystalQuickTM X plate (Greiner BioOne) on beamline BM30A-
FIP at the ESRF, equipped with an ADSC Q315r CCD detector. Only the
density obtained in chain A was sufﬁcient enough to build G418.
Both structures were reﬁned by molecular replacement using chain
A of the homologous APH(2″)-IVa·ADP complex (PDB: 4N57) after re-
moval of the ligand as search model. Data were processed and scaled
with XDS [20] and SCALA [21]. The atomic models were rebuilt in Coot
[22] and reﬁned using Refmac [23] with 10 sub-segments per protein
chain of torsion–libration–screw from the TLSMD server [24]. G418
and sisomicin restraints were generated with the PRODRG2 server[25]. The 2Fo − Fc omit maps were calculated with AutoBuild from the
PHENIXpackage [26] after omitting the aminoglycosidemolecules pres-
ent in the asymmetric unit. Data collection and reﬁnement statistics are
shown in Table 1 and the structures were deposited in the protein
databank (PDB: 5C4K and PDB: 5C4L). The B-factor values for G418
were large whichmay be explained by the high ﬂexibility of the amino-
glycoside in the binding site.
The structures were analyzed using the PyMOL Molecular Graphics
System (version 1.3, Schrödinger, LLC). The rmsd between non-
hydrogen atoms of different ligands was calculated using the pair ﬁt
command.
2.6. Kinetic experiments
Unless otherwise stated, kinetic experiments were carried out in a
buffer that contained 50mMTris, 40mMKCl, 1mM freeMgCl2 adjusted
to pH 7.5with HCl at 25 °C. The initial concentrations of aminoglycoside
and ATP are indicated in the ﬁgure legends. In the case of experiments
with CaATP, the buffer was MgCl2-free.
Steady state kinetics were carried out in thermostatically controlled
beakers as already described [27]. Unless otherwise stated, the enzyme
concentration was 0.5 μM in the presence of various concentrations of
aminoglycoside (5 to 100 μM). With amikacin and paromomycin, the
absence of activity was conﬁrmed at 5 μM APH(2″)-IVa. Reactions
were initiated by adding a saturating concentration of ATP (2.5 mM)
in a thermostatically controlled beaker containing APH(2″)-IVa and
aminoglycoside. At regular intervals, a volume of 80 μL of the reaction
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40 μL of perchloric acid at 10%. The precipitated protein was then re-
moved by centrifugation at 4 °C, 20 min at 19,000 g. ADP and ATP
were separated by HPLC (Waters) on an anion-exchange column
(SAX-Partisphere, AIT France). Themobile phasewas 200mMammoni-
um phosphate–HCl buffer at pH 5.5 and 10% acetonitrile. A 100 μL vol-
ume of the quenched reaction mixture was diluted in 900 μL of buffer
containing the mobile phase supplemented with 5 N KOH to readjust
the pH to 5.5. Quantiﬁcation of ADP and ATP was obtained by integrat-
ing HPLC peaks at 259 nm and their concentrations were reported rela-
tive to the enzyme concentration. Concentrations (in the quenched
reactionmixtures) between 0.5 and 500 μMof ADP or ATP gave a linear
and equivalent OD259 response. For each injected sample, the concen-
tration of ADP was calculated using the following equation, where
[ATP]i is the initial ATP concentration used in the experiment:
ADP½  ¼ ADP peak area ATP½ i
 
= ADP peak areaþ ATP peak areað Þð3Þ
Transient kinetic experiments were carried out at 25 °C in a QFM-
400 quench–ﬂow (Bio-Logic, France) or in a SF-61 DX2 stopped–ﬂow
(TgK Scientiﬁc, UK). In the quench–ﬂow method, APH(2″)-IVa, pre-
incubated with the aminoglycoside, wasmixedwith ATP in the appara-
tus. Themixtureswere aged for speciﬁc times (from 8ms to several sec-
onds), quenched in 10% perchloric acid and the ADP and ATP measured
byHPLC, as described above. Because perchloric acid dissociates all non-
covalent complexes, by thismethod, concentrations in the reactionmix-
tures of total ADP, that is to say enzyme-bound ADP plus free ADP, are
obtained [27]. In the stopped–ﬂow experiments, a free ADP ﬂuorescent
biosensor, MDCC-ParM [28], was included in the ATP solution. By this
method, concentrations in the reaction mixtures of free ADP only areFig. 1. Structure of the aminoglycosides investigated in this study. Substitutions on the 2-deoxys
that are discussed in the text.obtained. Experiments were carried out as previously described for
APH(3′)-IIIa [27].
3. Results
The structures of the eight aminoglycosides studied here are given in
Fig. 1.
3.1. Thermodynamic studies of aminoglycosides binding to APH(2″)-IVa
By isothermal titration calorimetry (ITC), we determined the ther-
modynamic parameters, and consequently the binding afﬁnities, of ami-
noglycoside binding to APH(2″)-IVa. Although ITC has been used
extensively to characterize aminoglycoside binding to APH(3′)-IIIa
[29–32] or to other aminoglycoside modifying enzymes [33–39], this
work brings theﬁrst data for APH(2″)-IVa. Fig. S1 shows the binding iso-
therms and parameters obtainedwith APH(2″)-IVa and eight aminogly-
cosides, ﬁtted with a single site model. Thermodynamic parameter
values obtained with 4,6- or 4,5-disubstituted aminoglycosides are in
Table 2. For all the aminoglycosides, the free energy changes, ΔG, were
negative upon binding to APH(2″)-IVa, indicating that the formation
of APH(2″)-IVa ∙ aminoglycoside complexes is favorable, even with
4,5-disubstituted aminoglycosides that are not substrates of this en-
zyme ([5] and conﬁrmed below). Values of ΔG range from −7.8 to
−5.6 kcal mol−1, corresponding to Kd of 2.3 to 82.2 μM.
Interestingly, there is a correlation between afﬁnity and aminoglyco-
side molecular weight as shown in Fig. 2a. Excluding kanamycin A and
amikacin, the two aminoglycosides having a hydroxyl instead of an
amino group in C2′ position (discussed later) that showed the lowest af-
ﬁnities, the smallest aminoglycosides exhibited the tightest binding totreptamine scaffold (4,5) or (4,6) are indicated. Dashed lines represent structural elements
Table 2
Dissociation constants and thermodynamic parameters from ITC titrations. Results obtainedwith different aminoglycosides and APH(2″)-IVa are expressed asmean± standard deviation
from two (for kanamycin B and G418) or three (for all the other aminoglycosides) independent experiments.MWandNCNO represent themolecular weight and number of non-hydrogen
atoms of aminoglycosides, respectively. Kd values were calculated from ITC-derived Ka. The value of−TΔS was determined at 25 °C. In the table, aminoglycosides are ranked from the
highest to the lowest afﬁnity for APH(2″)-IVa. Binding isotherms and ﬁts are given in Fig. S1.
Aminoglycosides MW
(g mol−1)
NCNO Kd
(μM)
ΔG
(kcal mol−1)
ΔH
(kcal mol−1)
−TΔS
(kcal mol−1)
Sisomicin 447.5 31 2.3±1.6 −7.8±0.4 −1.8±0.1 −6.0±0.4
Tobramycin 467.5 32 3.9±0.6 −7.4±0.1 −3.7±0.6 −3.7±0.7
Kanamycin B 483.5 33 5.7±1.1 −7.2±0.1 −3.8±0.2 −3.4±0.4
Gentamicin 463.6 33 9.7±5.0 −6.9±0.3 −2.5±0.2 −4.4±0.3
G418 496.6 34 27.5±3.3 −6.2±0.1 −4.8±0.1 −3.0±2.3
Paromomycin 615.6 42 63.6±29.0 −5.8±0.3 −2.5±0.2 −3.2±0.4
Kanamycin A 484.5 33 79.9±6.2 −5.6±0.1 −5.5±0.3 −0.1±0.2
Amikacin 585.6 40 82.2±8.9 −5.6±0.1 −4.0±0.1 −1.6±0.1
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gand efﬁciency, LE, a guide commonly used in drug discovery and lead
optimization [40,41]. Ligand efﬁciency is deﬁned as the ratio of−ΔG
to the number of non-hydrogen atoms of the ligand (NCNO). As shown
in Fig. 2b, ligand efﬁciency linearly depends on NCNO with the largest
aminoglycosides exhibiting the smallest ligand efﬁciencies. Consistent-
ly, there is a logarithmic dependence of Kd on ligand efﬁciency (Fig. 2c).
Does the presence of nucleotide affect APH(2″)-IVa afﬁnity for ami-
noglycosides? With APH(3′)-IIIa, the formation of binary enzyme ∙
aminoglycoside and ternary enzyme ∙ ATP ∙ aminoglycoside complexes
could be compared by the use of CaATP, because with it the enzyme is
inactive [30]. It was not possible to assess this question with APH(2″)-
IVa as CaATP is a substrate of this enzyme (Fig. 5a, see below). Instead,
we used MgADP or MgAMP-PNP and showed that the pre-incubation
of the enzymewith the nucleotide has no signiﬁcant effect on its afﬁnity
for aminoglycoside or on binding thermodynamic properties. For exam-
ple, with kanamycin A, the Kd values were 87± 8 μM in the presence of
870 μMMgADP, 103±12 μM in the presence of 1mMMgAMP-PNP and
80 ± 6 μM in the absence of nucleotide.
3.2. Electrostatic potential and free energy change calculations
In order to determine the nature of the preponderant interactions
governing the aminoglycoside binding to APH, the electrostatic poten-
tial surface of kanamycin A, tobramycin and sisomicin was computed
(Fig. 3a to c) and showed obvious differences in their charge distribu-
tion. Indeed, for tobramycin and sisomicin, the supplementary positive-
ly charged amino group in 2′ position induces a very large positive
surface compared to that of kanamycin A. This should be highly favor-
able to strong binding to APH(2″)-IVa, since the aminoglycoside binding
site is fully negatively charged (Fig. 3d).
The binding free energymeasured by ITC for the different aminogly-
cosides showed very small differences. Therefore, in order to explore
thoroughly these small energy barriers, molecular dynamics simula-
tions using the ABF method were carried out on several complexes.
Free energy calculations and the resulting PMF (estimation of the ener-
gy required for ligand release) are shown in Fig. 3e.
As expected, the force required to unbind the aminoglycoside was
similar for the three aminoglycosides tested. However, one can notice
a higher PMF obtained in the case of tobramycin and sisomicin as com-
pared to kanamycin A. These differences in terms of free energy are in
good agreement with the values obtained by ITC. Indeed, the ΔG values
of−5.6,−7.4 and−7.8 kcal mol−1 measured by ITC for kanamycin A,
tobramycin and sisomicin were comparable to the PMF values which
were 5.4, 8.2 and 8.1 kcal mol−1, respectively (values at the end of the
simulation, with opposite sign to ΔG as unbinding is measured here).
Comparison of such theoretical values should be taken with care, as
the full binding process is not computed, but instead just the release
of the aminoglycoside.
Interestingly, the dissociation of the aminoglycoside seems to be
governed by the NH3+ groups that link successively numerous Asp orGlu residues present at the periphery of the aminoglycoside binding
site. This is shown by the different phases punctuating the PMF curves
(Fig. 3e) and this may reﬂect the entry or the exit pathway of the
aminoglycoside.
3.3. Structure determination of APH(2″)-IVa ∙ aminoglycoside
binary complexes
In order to characterize interactions between enzyme and ligands,
we determined the crystal structures of APH(2″)-IVa bound to amino-
glycosides with different afﬁnities.
A crystal structure of APH(2″)-IVa in complex with sisomicin, that
has the lowest Kd of the eight aminoglycosides tested here, has been
solved at a resolution of 2.35 Å (Fig. S2). However, the binding position
of the aminoglycoside in chain B is probably induced by the crystal
packing. Indeed, sisomicin is stabilized by an interaction with the back-
bone of Ser136, which belongs to a symmetric protein of the unit cell.
This feature shifts the position of the aminoglycoside from its presumed
physiologically relevant orientation. In chain A, the electron density ob-
tained permits only to build the ring A of sisomicin. The rest of themol-
ecule is probably too ﬂexible to be visualized. In both chains, sisomicin is
stabilized by salt bridges occurring between the side chains of Glu235
and Glu268 and the 6′-NH3+ of the aminoglycoside and by hydrophobic
interaction between Trp271 and ring A.
We solved the structure at a resolution of 3.05 Å of APH(2″)-IVa in
complex with G418 (geneticin), that has an intermediate afﬁnity for
APH(2″)-IVa. Comparison of the crystal structures of binary complexes
with tobramycin, kanamycin A and G418 (PDB: 3SG8, 4DFB and 5C4K,
respectively) shows that the position of the three aminoglycosides is
highly similar with an rmsd (between ligands non-hydrogen atoms)
of 0.59 Å between kanamycin A and G418 and of 0.36 Å between
tobramycin and G418 (Fig. 4).
As already observed in the previous published structures, Glu235
stabilizes rings A and B of the aminoglycoside (Fig. 4a, d, g). Interesting-
ly, the interaction between Glu238 and the ring A of aminoglycoside is
maintained even if the substituent in the 6′-position of G418 is different
(Fig. 4b, e, h). However, its interaction with ring B is, in turn, abolished.
Similar to kanamycin A and tobramycin structures, ring C is maintained
by an interaction with Asp197. In general, the APH(2″)-IVa ∙ G418 com-
plex is characterized by less interactions than the binary complex with
tobramycin, which may be at the origin of the weaker afﬁnity of G418
compared to tobramycin.
3.4. Steady state and transient kinetics by direct assessment of
ADP production
In order to see if the differences in the binding afﬁnity of aminogly-
cosides affect the enzymatic reaction rate constants, we carried out
steady state and transient kinetic experiments. Here, we used a direct
method for separating and quantifying ADP and ATP by HPLC in APH
Fig. 2. Relationship between the size of aminoglycosides and their afﬁnity for APH(2″)-IVa
determined by ITC. (a) Representation of the Kd value as a function of the molecular
weight of aminoglycosides. Data for kanamycin A and amikacin have been excluded
from analysis. (b) Representation of the ligand efﬁciency, LE, as a function of the number
of non-hydrogen atoms of aminoglycoside (NCNO). (c) Dependence of the logarithm of
Kd (pKd) on LE. Dashed lines indicate the general tendencies.
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With this method, concentrations of ADP down to 0.5 μM can be
measured.
In addition to its phosphotransferase activity, in the absence of
aminoglycoside, APH(2″)-IVa has a low ATPase activity of 0.014 s−1
with 2 mM MgATP (Fig. 5a). Its phosphotransferase activity in thepresence of 2 mM CaATP as phospho-donor and kanamycin A as accep-
torwas low compared to thatwithMgATP, but not negligible (0.092 and
0.84 s−1, respectively). Typical time courses of the phosphotransferase
activity at two different initial concentrations of MgATP are illustrated
in Fig. 5b. It is noteworthy that in each case the reaction went to near
completion, which is to say that ATP was completely converted into
ADP. Steady state rates were obtained from the initial linear portions
(Fig. 5c).
The steady state parameters, kcat and Km, obtained with 8 aminogly-
cosides and with MgATP as phosphate donor, are summarized in
Table 3. As can be seen, with the exception of tobramycin, our values
are in reasonable agreement with those of Toth et al. using the coupled
enzyme system [5].With tobramycin, Toth et al. reported a Km of 1.5 μM
whereas we obtained 13.2 μM.We are unable to explain this difference,
but this could potentially be a consequence from using a coupled assay
versus a direct method such as the quench–ﬂow assay.
The variation of the ratio Kd/Km between aminoglycosides is striking
— from 20with kanamycin A to 0.3with tobramycin. Are these different
ratios explained by differences in the kinetics of the transient formation
of enzyme ∙ADP complex?Using the same quenching/samplingmethod
and a rapid quench–ﬂow apparatus, we could measure transient kinet-
ics of totalADP production catalyzed by APH(2″)-IVawith kanamycin A,
tobramycin, G418 or sisomicin and ATP, as illustrated in Fig. 6 (circles).
Except the nature of the antibiotic, the four experiments were car-
ried out under identical conditions. Each time course for the production
of totalADP (that is to say, free ADP plus enzyme-bound ADPwhich dis-
sociates with the acid quenching) consists of two phases: a burst of ADP
followed by the steady state. These traces suggest that an ADP-
containing complex or free ADP is rapidly formed compared to the
steady state rate of the reaction.
In parallel, and in the same experimental conditions, we used ﬂuo-
rescence stopped–ﬂow with an ADP biosensor in order to measure the
kinetics of freeADPproduction. The reactionwas followedbymeasuring
the ADP-induced ﬂuorescence increase of MDCC-ParM as a function of
time. Results are shown in Fig. 6 as continuous lines. Interestingly, the
time courses of free ADP production showed a lag preceding the steady
state, the amplitude and rate constant of which are similar to those de-
termined for the burst of total phosphate. This suggests that free ADP is
not formed rapidly compared to the steady state rate of the reaction, but
instead an ADP-containing complex — the lag is a reﬂection of the time
needed to build up this intermediate. Values for the amplitudes and rate
constants of the burst/lag phases and the steady state rate constants are
summarized in Table 4.
The transient kinetic parameters determined here did not show
large differences between the aminoglycosides, although there may be
a correlation between kcat and the transient rate constants (klag and
kburst). Also, transient rate constants were not very large compared to
the steady state rate constants. This is especially true for tobramycin
with only a 2 to 3-fold difference. Altogether, these results suggest
that with all aminoglycosides, even those with a low afﬁnity for the en-
zyme, the product release is the rate limiting step of the reaction, but the
phosphotransfer step, that leads to the production of ADP-containing
complex, may also contribute.
4. Discussion
4.1. Comparison of thermodynamic parameters of different
aminoglycoside phosphotransferases
APH(2″)-IVa is speciﬁc for 4,6-disubstituted aminoglycosides as
phosphate acceptors. In comparison, APH(3′)-IIIa has a broader speciﬁc-
ity for antibiotics— it can use 4,5- aswell as 4,6-disubstituted aminogly-
cosides. It is therefore interesting to compare the aminoglycoside
afﬁnities of APH(3′)-IIIa and APH(2″)-IVa, two enzymes that catalyze
the same reaction but on different positions on the aminoglycoside
and with a different substrate speciﬁcity. The Kd values determined
Fig. 3. Electrostatic potential surface representation of kanamycin A (a), tobramycin (b) and sisomicin (c) computed using Adaptive Poisson–Boltzmann Solver (probe radius 1.4 Å).
The blue and red surfaces show the positive and negative isosurfaces of the electrostatic potential at ±10 kT/e, respectively. (d) The same representation as in previous panels but for
APH(2″)-IVa (PDB: 4DFB in the absence of kanamycin A). (e) Potential of mean force (PMF) computed from dynamics simulations using the ABF method for unbinding kanamycin A
(Δ), tobramycin (□) and sisomicin (○). The reaction coordinate was deﬁned by the distance separating the two centers of mass (APH and aminoglycoside). Insert: snapshots showing
the kanamycin unbinding as a function of time during the simulation (each center of mass is depicted as a red or blue sphere).
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measured by Özen and Serpersu [30] with APH(3′)-IIIa (Kd between
0.3 and 92.6 μM). With both phosphotransferases, amikacin shows a
much lower afﬁnity relative to other aminoglycosides, probably due to
its bulky substituent at position N1.
Another difference between these two phosphotransferases is that
the afﬁnity for aminoglycosides depends on the antibiotic size with
APH(2″)-IVa, but not with APH(3′)-IIIa. With APH(2″)-IVa, this correla-
tionmay be the effect of entropic contributionswhere longer substrates
are restricted in degrees of freedom in the binding site, without proper
compensation with enthalpic terms, since the additional residues of the
substrate are not interacting strongly with the enzyme. This suggests
that the binding site on APH(2″)-IVa is less extensible and dynamic
than that of APH(3′)-IIIa. Indeed, molecular dynamics simulations [42]
showed that a highly ﬂexible loop of APH(3′)-IIIa (V154-K166), posi-
tioned over the antibiotic binding pocket and colored in red in Fig. 7a,
becomes more constrained in the presence of kanamycin A, with
which it interacts. The ﬂexibility of this loop may explain the ability of
the APH(3′)-IIIa to accommodate aminoglycosides with various sizes,
contrary to the APH(2″)-IVa. Indeed, this loop is not present in the latter
(Fig. 7b), which probably limits the binding of 4,5-disubstituted amino-
glycosides or, at least, dramatically decreases their afﬁnity for the
protein.However, this alone does not explain the lack of catalytic activity of
APH(2″)-IVa with the 4,5-disubstituted aminoglycosides. Instead, unfa-
vorable positioning of the 2″-site may be the reason. This is similar to
what is observed with the aminoglycoside nucleotidyltransferase(2″)-
Ia, to which neomycins bind tighter but are not substrates of the en-
zyme. In this case, the 2″-site becomes too distant to the α-phosphate
group for a direct nucleophilic attack [35]. Thus, unfavorable orientation
of the 2″-site in the more constrained binding site on APH(2″)-IVa may
be correlated with its inability to catalyze phosphotransfer with 4,5-
disubstituted aminoglycosides.
4.2. Comparison of the interactions between APH(2″)-IVa and aminoglyco-
side in the crystal structures
Five APH(2″)-IVa ∙ aminoglycoside binary complexes have been
solved by X-ray crystallography: two in the presence of kanamycin A
(PDB: 4DFB [43] and PDB: 3SG9 [6]), one with tobramycin (PDB: 3SG8
[6]), one with G418 (PDB: 5C4K, here) and one with a partially solved
sisomicin (PDB: 5C4L, here).
In the structures determined by Shi et al. [6], the superposition of the
two different aminoglycosides reveals similar binding positions, except
for ring C, coplanar to ring A for kanamycin A and lightly tilted for
tobramycin (Fig. 8a). High resolution electron densities were visible
Fig. 4. Comparison of tobramycin, kanamycin A and G418 binding to APH(2″)-IVa. Crystal structures of APH(2″)-IVa in complex with (a, b) kanamycin A, (d, e) tobramycin or (g, h) G418
with the ligand contoured with the 2Fo− Fc omit map (gray) at a sigma level of 1. Respective details of interactions are shown for kanamycin A (c), tobramycin (f) and G418 (i). The left
panels show the interactions of Glu235 with the aminoglycosides. Middle panels show interactions of Glu238. The aminoglycosides are ﬁgured in stick representation and ring
nomenclature is shown. The major interactions observed between the three aminoglycosides and the APH(2″)-IVa residues are shown as dashed lines.
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In contrast, we found that the density obtained for both chains of
APH(2″)-IVa ∙ kanamycin A complex (3SG9) was not sufﬁcient to
completely build the ligand (Fig. 8c), resulting in much larger B-factor
values than the surrounded residues. Nevertheless, the superposition
of the APH(2″)-IVa ∙ tobramycin structure (3SG8) and that with kana-
mycin A solved by Shakya et al. (4DFB) shows identical positioning of
aminoglycosides in the binding site (Fig. 8d) and very slight modi-
ﬁcations of interacting amino acid side chains. The electron density
obtained for 4DFB fully covers the aminoglycoside substrate (Fig. 8e).
We consequently decided to use the 4DFB structure for following
discussion.
Comparing the APH(2″)-IVa ∙ tobramycin (Fig. 8b) and the APH(2″)-
IVa ∙ kanamycin A (Fig. 8e) binary structures, most interactions between
the aminoglycoside and protein residues are conserved. Nevertheless,
there may be a supplementary H-bond between Glu268 and the 3′-
OH of kanamycin A which is not present in the tobramycin structure,
not substituted in 3′ (Fig. 8b and e). However, this interaction may be
weak because the distance measured between the 3′-O of kanamycin
and the δ-O of Glu268 is rather long for a H-bond (3.57 Å) in chain B
and it does not exist in the chain A, where Glu268 occupies an alterna-
tive position as shown in Fig. 4a. More importantly, the H-bond formed
between Glu235 and 2′-OH of kanamycin A is replaced by a salt bridge
with 2′-NH3+ of tobramycin or G418. As a result, the afﬁnity of the
apoprotein is 20 times greater for tobramycin than for kanamycin A
and for amikacin which also lacks a 2′-NH3+.4.3. Effect of different substituents of aminoglycosides on APH(2″)-IVa
afﬁnity and catalytic activity
In comparison with other aminoglycosides, the different substitu-
ents in positions C3″, C4″ and C5″ of gentamicin, G418 and sisomicin
do not alter signiﬁcantly the afﬁnity for APH(2″)-IVa. We note that
these three aminoglycosides have the lowest kcat and Km values of the
eight tested. Since they also presentmodiﬁcations on ringA, it is difﬁcult
to draw clear conclusions concerning the effect of ring C substituents.
However, the crystal structure of the APH(2″)-IVa ∙ G418 complex
shows that the hydroxyl and methyl groups on the C6′ of G418 do
not create novel interactions with the protein (Fig. 4h and i). The
absence of a primary amine on C6′ of ring A seems to affect the
binding afﬁnity of aminoglycosides for APH. Indeed, G418 has a
weaker afﬁnity for the apoprotein than gentamicin, with a second-
ary amine at C6′, and even weaker than sisomicin with a primary
amine. The crystallographic structure obtained in the presence of
sisomicin shows that the aminoglycoside is stabilized by salt brid-
ges between 6′-NH3+ and Glu235 and Glu268 (Fig. S2). An interac-
tion of 2′-NH3+ of sisomicin with Asn228 may also play a role.
Even if these data are incomplete or biased by the crystal packing,
these results highlight the importance of 2′- and 6′-NH3+ groups
in the binding of aminoglycosides, explaining the very high afﬁni-
ties obtained by ITC.
Docking of sisomicin predicts a similar position of binding compared
to the crystal structure (Fig. S2e and h). Indeed, the 2′- and 6′-amines
Fig. 5. Time courses of ADP formation by the quenching method and HPLC analysis.
(a) Time courses of MgATPase (●, kss = 0.014 s−1), CaATP phosphotransferase (□,
kss = 0.092 s−1) and MgATP phosphotransferase (○, kss = 0.84 s−1) activities. APH(2″)-
IVa concentration was 0.5 μM, kanamycin A was 0 or 100 μM, and MgATP or CaATP was
2 mM. (b) Complete time courses for MgATP phosphotransferase activity at 5 μM
APH(2″)-IVa, 500 μM kanamycin A and 100 (○) or 200 (□) μM ATP. (c) Initial portions
of the time courses showing linearity up to 30 s at 0.5 μM APH(2″)-IVa, 100 μM
kanamycin A and 100 (○) or 200 (□) μM MgATP. The experiments were done in
triplicate. The steady state rate constants were 0.23 s−1 and 0.37 s−1, respectively.
Table 3
Steady state kinetic parameters and dissociation constants for aminoglycosides. Kinetic
parameters were obtained at saturating concentration of MgATP (2.5 mM) and variable
concentrations of aminoglycoside (0 to 100 μM) with APH(2″)-IVa. Results are expressed
as mean ± standard deviation from at least two independent experiments. Aminoglyco-
sides are ranked from the highest to the lowest catalytic efﬁciency (kcat/Km). For compar-
ison, values obtained by Toth et al. [5] are mentioned in brackets, and the Kd values
measured by ITC are shown.
Aminoglycosides kcat
(s−1)
Km
(μM)
kcat/Km
(μM−1 s−1)
Kd
(μM)
Kd/Km
Kanamycin A 0.90±0.02 4.0±0.5 0.225 79.9±6.2 20.0
(0.92±0.01) (3.3±0.3) (0.279) – –
G418 0.49±0.01 2.2±0.4 0.223 27.5±3.3 12.5
Sisomicin 0.73±0.02 3.5±0.6 0.209 2.3±1.6 0.7
Gentamicin 0.47±0.01 3.3±0.6 0.142 9.7±5.0 2.9
Kanamycin B 1.69±0.11 12.5±2.9 0.135 5.7±1.1 0.5
Tobramycin 1.64±0.08 13.2±2.2 0.124 3.9±0.6 0.3
(1.80±0.03) (1.5±0.1) (1.200) – –
Amikacin na na na 82.2±8.9 –
(0.15±0.01) (98.0±15.0) (0.002) – –
Paromomycin na na na 63.6±29.0 –
na: no detectable activity (b0.001 s−1), even by increasing the enzyme concentration up
to 5 μM.
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Glu268. However, the predicted binding mode shows that the 2′-NH3+
group of sisomicin is lightly shifted towards Glu235, creating more in-
teractions with the glutamate residues. The presence of a double bondwhichmakes the A ringmore rigid should drastically reduce the confor-
mational freedom of the ring and therefore may stabilize the binding of
the aminoglycoside by favoring a particular ring orientation.
The difference in position 1 of amikacin compared with the other
aminoglycosides results in a dramatic lowering of its catalytic efﬁciency.
However, this different substituent does not affect much its binding to
the apoenzyme as its Kd is very similar to that of kanamycin A
(82.2 μM and 79.9 μM, respectively). The bulky group in the C1 position
of amikacin may induce steric hindrance which could be deleterious for
the phosphotransfer on the 2″-OH.
4.4. Interpretation of APH(2″)-IVa transient kinetic data
As a ﬁrst approximation, we interpret our data via Scheme 1 in
which APH represents APH(2″)-IVa, AMG aminoglycoside and AMG-P
the corresponding 2″-phosphorylated aminoglycoside.
The steps 1 to 5 are described by the forward rate constants k+i and
the backward rate constants k−i. For simplicity, in Scheme 1 substrate
binding and product release steps are shown as single steps, but they
are most probably composed of two steps: a rapid equilibrium leading
to the formation of the collision complex, followed by a conformational
change. Toth et al. [5] proposed that APH(2″)-IVa catalyzes the
phosphotransfer by a randommechanism, that cannot exclude the pos-
sibility that the binding of one substrate affects the binding of the other
(that is to say K1 ≠ K2′ and K1′ ≠ K2). Isothermal titration calorimetry ex-
periments carried out here gave information on step 1. The Kd for ami-
noglycoside represents the equilibrium constant of aminoglycoside
binding step, that is K1 = k−1/k+1. In our experimental conditions, we
measured a 20-fold larger Kd for kanamycin A compared to tobramycin.
Now, unexpectedly, under catalytic conditions, that is in the presence of
ATP, the enzyme had a 3.3-fold lower Km for kanamycin A compared
with tobramycin. Segel proposed that, if the ratio Km/Kd for a given sub-
strate is b1, there is substrate synergy by which the binding of one sub-
strate increased the afﬁnity for the second [44]. On the other hand, if the
ratio is N1, there is substrate antagonism (for a recent discussion, see
[45]). With the caveat that a Km is not a simple dissociation constant
for the formation of a ternary enzyme complex, this suggests that the
presence of ATP may have different effects on the interactions of kana-
mycin A and tobramycin with the enzyme, although we showed that
ADP or AMP-PNP did not.
Alternatively, it could be that for efﬁcient catalysis, the aminoglyco-
side must not be too strongly bound to the phosphotransferase to allow
the rapid release of the phosphorylated antibiotic. Thus, if the phos-
phorylated aminoglycoside interacts tightly with the enzyme, it could
Fig. 6. Rapid quench–ﬂow (circles) and stopped–ﬂow (lines) time courses of ADP formationwith different aminoglycosides. The quench–ﬂow reactionmixtures contained 5 μMAPH(2″)-
IVa, 500 μM ATP and 100 μM kanamycin A (a), tobramycin (b), G418 (c) or sisomicin (d). Time courses ﬁtted to a single exponential burst followed by a steady state. In stopped–ﬂow
experiments, the reaction mixtures were the same, plus 50 μMMDCC-ParM. Time courses ﬁtted to an initial lag (ﬁtted with a single exponential) followed by a steady state. Values of
ﬁtted parameters are given in Table 4.
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the accumulation of intermediates that involve the products. We con-
ﬁrmed this by transient kinetics: starting with APH ∙ AMG plus ATP,
the time course of total ADP formation was biphasic with a rapid burst
of ADP preceding the steady state rate whereas that of free ADP was bi-
phasic with a lag instead of the burst. These observations suggest that
intermediates containing ADP (APH ∙ AMG-P ∙ ADP and/or APH ∙ ADP)
accumulate in the steady state. Therefore, we can conclude that with
APH(2″)-IVa, steps 2 and 3 are fast compared to step 4 or 5′. It implies
that ADP release, step 4 or 5′, is rate-limiting. We note that with three
different APH(3′), a product release step is also rate limiting [27,46,47].
However, the observation that the transient rate constants mea-
sured here were not much larger than steady state rate constants, sug-
gests that step 3 may not be much faster than the product release
steps. To evaluate the relative contribution of each step on the transient
and steady state kinetics, we intend to study the dependence of
the transient amplitudes and rate constants as a function of theTable 4
Kinetic parameters determined from transient kinetic experiments. Transient amplitudes (Abu
determined from the total (quench–ﬂow) or free (stopped–ﬂow) ADP time courses are reporte
512 (stopped–ﬂow) time points. Experimental conditions are given in Fig. 6.
Aminoglycosides Quench–ﬂow
Aburst
(mol/mol)
kburst
(s−1)
kss
(s−1)
Kanamycin A 0.38±0.04 3.4±0.7 0.77±
G418 0.34±0.11 2.0±1.1 0.35±
Sisomicin 0.48±0.07 2.0±0.4 0.50±
Tobramycin 0.44±0.05 2.1±0.4 1.08±aminoglycoside or ATP concentrations, and starting from the apoen-
zyme or binary complexes.
Shi and Berghuis published crystal structures of APH(2″)-IVa in com-
plexwith adenosine and guanosine that provide explanation for the pe-
culiar dual nucleotide speciﬁcity of this enzyme [48]. Therefore, it would
be interesting to compare the transient kinetic rate constants obtained
using MgATP or MgGTP as phosphate donor, to determine if the
phosphotransfer step is similarly fast with the two nucleotides.
5. Conclusions
Altogether, our study strongly suggests that two primary amino
groups are required for a tight binding of the aminoglycoside to
APH(2″)-IVa. The presence of both amino groups in position 2′ and 6′
leads to strong afﬁnities by interacting with Glu235 and Glu238, res-
pectively. In addition, itmust be highlighted that the binding of the ami-
noglycoside to APH is mainly driven by electrostatic interactions.rst and Alag), transient rate constants (kburst and klag) and steady state rate constants (kss)
d. Standard errors are from ﬁtting of single curves composed of 26–29 (quench–ﬂow) or
Stopped–ﬂow
Alag
(mol/mol)
klag
(s−1)
kss
(s−1)
0.02 −0.35±0.01 3.4±0.1 0.70±0.01
0.04 −0.31±0.01 1.6±0.1 0.33±0.01
0.02 −0.44±0.01 1.6±0.1 0.48±0.01
0.02 −0.48±0.01 3.3±0.1 1.05±0.01
Fig. 7. Comparison of aminoglycoside binding site of APH(3′)-IIIa and APH(2″)-IVa. (a, b) Structures of the APH(3′)-IIIa (PDB: 1L8T, green) and the APH(2″)-IVa (PDB: 4DFB, blue),
respectively. The loop V154-K166 is colored in red in the 1L8T structure. (c) Superposition of the two structures.
Fig. 8. Crystal structures of APH(2″)-IVa ∙ aminoglycoside binary complexes. The enzyme is shown in cartoon representation and the substrate in sticks. (a) Superposition of tobramycin in
brown (PDB: 3SG8, chain A) and kanamycin A in purple (PDB: 3SG9, chain A) structures. (b, c) Individual APH(2″)-IVa ∙ tobramycin and APH(2″)-IVa ∙ kanamycin A complexes,
respectively. Aminoglycosides are contoured by their 2Fo − Fc electron density mesh at 1.0 σ (gray). Interacting residues are represented in cyan sticks and interaction highlighted
by dashed lines. The electron density maps were from the Electron Density Server (EDS). (d) Superposition of APH(2″)-IVa ∙ tobramycin in brown (3SG8, chain A) and APH(2″)-
IVa ∙ kanamycin A in blue (PDB: 4DFB, chain B) structures. (e) 2Fo− Fc electron density map obtained in 4DFB.
812 E. Kaplan et al. / Biochimica et Biophysica Acta 1860 (2016) 802–813However, a better afﬁnity is not correlated with a better catalytic
efﬁciency.
We show that the reaction catalyzed by APH(2″)-IVa is kinetically
limited by the release of product. These results may provide further
insights into the mechanisms by which bacteria evolved to combat
aminoglycoside antibiotics and may aid in the design of speciﬁc drugs
that overcome this resistance.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbagen.2016.01.016.Scheme 1. Random bi–bi mechanism of the phospTransparency document
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